Next Article in Journal
Aldehyde Dehydrogenase 2 Ameliorates Chronic Alcohol Consumption-Induced Atrial Fibrillation through Detoxification of 4-HNE
Next Article in Special Issue
The Role of Vesicle Trafficking Defects in the Pathogenesis of Prion and Prion-Like Disorders
Previous Article in Journal
Deleterious Alteration of Glia in the Brain of Alzheimer’s Disease
Previous Article in Special Issue
N-Terminal Regions of Prion Protein: Functions and Roles in Prion Diseases
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 21
Issue 18
10.3390/ijms21186677
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Prion Protein at the Leading Edge: Its Role in Cell Motility

by
Mariana Brandão Prado
†,
Maria Isabel Melo Escobar
†,
Rodrigo Nunes Alves
†,
Bárbara Paranhos Coelho
,
Camila Felix de Lima Fernandes
,
Jacqueline Marcia Boccacino
,
Rebeca Piatniczka Iglesia
and
Marilene Hohmuth Lopes
*
Department of Cell and Developmental Biology, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-000, Brazil
*
Author to whom correspondence should be addressed.
†
These authors contributed equally for this work.
Int. J. Mol. Sci. 2020, 21(18), 6677; https://doi.org/10.3390/ijms21186677
Submission received: 1 August 2020 / Revised: 8 September 2020 / Accepted: 9 September 2020 / Published: 12 September 2020
(This article belongs to the Special Issue Prions and Prion Diseases)
Browse Figures
Versions Notes

Abstract

:
Cell motility is a central process involved in fundamental biological phenomena during embryonic development, wound healing, immune surveillance, and cancer spreading. Cell movement is complex and dynamic and requires the coordinated activity of cytoskeletal, membrane, adhesion and extracellular proteins. Cellular prion protein (PrPC) has been implicated in distinct aspects of cell motility, including axonal growth, transendothelial migration, epithelial–mesenchymal transition, formation of lamellipodia, and tumor migration and invasion. The preferential location of PrPC on cell membrane favors its function as a pivotal molecule in cell motile phenotype, being able to serve as a scaffold protein for extracellular matrix proteins, cell surface receptors, and cytoskeletal multiprotein complexes to modulate their activities in cellular movement. Evidence points to PrPC mediating interactions of multiple key elements of cell motility at the intra- and extracellular levels, such as integrins and matrix proteins, also regulating cell adhesion molecule stability and cell adhesion cytoskeleton dynamics. Understanding the molecular mechanisms that govern cell motility is critical for tissue homeostasis, since uncontrolled cell movement results in pathological conditions such as developmental diseases and tumor dissemination. In this review, we discuss the relevant contribution of PrPC in several aspects of cell motility, unveiling new insights into both PrPC function and mechanism in a multifaceted manner either in physiological or pathological contexts.

Graphical Abstract

1. Introduction

Cell motility is a fundamental process that entails intracellular remodeling, an intricate molecular network, and several cell–milieu interactions [1]. Motile cells are essential for several biological events, such as morphogenesis [2], angiogenesis [3], muscle contraction [4], vesicle transport [5], wound healing [6] and immune response, as well as for pathological events. Most cell types in different tissues are capable of migrating on a substrate, and cellular locomotion is governed by different processes [7]. Actin represents one of the main proteins in the cytoskeleton and its polymerization is key in the assembly and dynamic behavior of microfilaments [8]. Those microfilaments play a major role in the generation of cell polarity, since they are responsible for the formation of dynamic membrane protrusions of the cell edge, such as lamellipodia, filopodia, cell cortex, microvilli, as well as stress fibers that generate focal adhesions (FA) to the substratum, and in cytokinesis for cell division [9]. Cell migration capacity is of great importance not only for the correct function of the organism, but also for development, remodeling of adult tissue, and wound healing [10].
Abnormal cell motility contributes to a number of illnesses such as neuronal development disorders, immunodeficiency, cancer, and neurodegenerative diseases [11]. In cancer, the migration of tumor cells leads to invasion and metastasis—both processes being crucial for tumor development and poor response to treatment, and decisive for patient survival [12].
Cellular movement phenomena require the orchestration of numerous extra- and intracellular multiprotein complexes, and the cellular prion protein (PrPC), a cell membrane molecule, seems to have a pivotal role in cell movement in several aspects. PrPC is encoded by the PRNP gene, and its expression is detected very early in the post-implantation embryo [13], being involved in the regulation of different mammalian stem and progenitor cell proliferation and differentiation mechanisms [14]. PrPC is expressed in neurons and in most neural cell types, modulating astrocyte development [15], oligodendrocyte proliferation [16], and proper functioning of microglia in early stages [17]. Besides the central nervous system (CNS), PrPC is also expressed in cells of the peripheral nervous system (PNS) [18], as well as in organs and tissues of other systems, such as the heart, intestine and pancreas [19].
PrPC is organized into two main domains: a less flexible C-terminal domain of globular structure, with a glycophosphatidylinositol (GPI) membrane anchor [20,21,22], and a flexible and less organized N-terminal domain containing octapeptide repeats [23,24], closely related with the binding of PrPC to a number of protein partners [25,26]. PrPC is located on lipid rafts, which are cholesterol-rich portions of the cell surface highly associated with activation of signaling cascades [27], and can couple with plenty of membrane receptors located in these niches, forming multiprotein signaling platforms [27,28,29]. PrPC ligands in the physiological and pathological contexts include transmembrane proteins, ion channels, extracellular matrix proteins and several secreted molecules including stress inducible protein 1 or heat shock organizing protein (STI1/HOP) [30,31,32,33]. The major PrPC ligands described are molecules related to adhesion and migration processes, such as neural cell adhesion molecule 1 (NCAM1), laminin, and laminin receptors [27]. Indeed, recent data from our group have shown that the modulation of PrPC expression can affect E-cadherin recruitment to the surface and cell migration in glioblastoma stem cells [31], demonstrating a relevant involvement of PrPC in these processes. PrPC also plays an important role in cell adhesion during zebrafish gastrulation [34] and migration of brain endothelial cells [35], forms adherens junction (AJ) with E-cadherin and F-actin in epithelial cells [36] and induces reorganization of the actin cytoskeleton in human T cells [37], among other hallmark features related to the motility of several types of cells.
This review discusses the biological processes involved in cell motility and migration, highlighting the participation of PrPC as a signaling organizer in these mechanisms for the proper functioning of cells under physiological conditions, as well as in the progression of cancer, focusing on PrPC as a player in invasion and metastasis events of several types of neoplasm.

2. Prion Protein in Dynamic Cell Movement

Functional components that actively participate in several aspects of cell motility processes are located on dynamic multi-molecular platforms on the plasma membrane. PrPC, a versatile protein with scaffold property, represents a potential molecule able to orchestrate the activity of signaling modules on the cell membrane involved in cellular migration. In this section, we discuss the pivotal role played by PrPC in modulating different motility phenomena, highlighting its interaction with proteins that regulate cell–cell and cell–matrix adhesion, as well as other novel partners in the context of the multi-step migration process.
As previously mentioned, PrPC expression is high in the CNS and PNS, where its function has been extensively studied. The role played by PrPC in the control of synapses, myelination, neuronal survival, and differentiation conceive this protein as a prominent neurotrophic modulator [30,38,39]. Following differentiation, neuron cells attach to the extracellular matrix (ECM) and start to project cytoplasmic extensions of the cell body, called neurites, in order to migrate [40]. PrPC modulates neurite outgrowth and neuronal survival when secreted as a soluble molecule, working as a ligand for signal transduction proteins [30,41]. The neurite growth process, in turn, requires cytoskeleton remodeling, and complete depletion of PrPC leads to β1 integrin aggregation, FA turnover, and increased stability of actin filaments, ultimately resulting in impaired neurite sprouting [42]. FA comprises structures rich in cell adhesion molecules (CAMs) such as integrin, an α/β heterodimeric adhesion glycoprotein receptor that clusters when bound to its ligand, thereby forming multiprotein complexes for intracellular signaling and actin cytoskeleton remodeling [43]. Moreover, FA formation is regulated by Ras homolog family member A (RhoA) activity which, in turn, is modulated by c-Src and focal adhesion kinase (FAK) proteins [44,45]. Additionally, PrPC signaling has been suggested to impact axon guidance.
Growth cones are essential for guiding the process of neurite sprouting, which is fundamental for the morphogenesis of the nervous system [46]. The growth cone per se is divided into two regions: the central domain, rich in microtubules and other associated proteins, and the peripheral domain, rich in actin filaments [47]. The polymerization of those filaments results in lamellipodia and filopodia-like protrusions with membrane receptors at their tips, sensing a variety of extracellular factors of the environment that act as guidance cues for this process [48]. PrPC was found to be accumulated at the tip of filopodia in growth cones and in cell–cell connection sites. It has been observed that the upregulation of the protein in these specific sites is accompanied by growth cone extension and formation of AJ and nanotubes [49]. In agreement, challenging the notion that PrPC knockout (KO) had no major deleterious effects in early mouse embryos [50], Bradikov and collaborators showed that hippocampal neurons lacking PrPC had smaller neurites and growth cones [51]. More specifically, PrPC is able to cluster in reggie membrane microdomains [52], activating the Src-kinase Fyn and Mitogen-activated protein kinase (MAPK), dynamically regulating the polarized transport of membranes and membrane proteins, such as N-cadherin, to the growing tip of neurons [51] (Figure 1). This turnover of membranes and membrane proteins in the growth cone is a fundamental step to the correct targeting and subsequent elongation of neurites towards the right direction of impulse, ensuring correct nerve cell connections [53]. In addition, it is known that the activation of integrin receptors may cause an influx of Ca2+ that affects membrane trafficking and reorganization of the growth cone [54]. PrPC-KO leads to a reduction in the number and trafficking of vesicles containing N-cadherin, an important component of AJ, diminishing N-cadherin association with reggie microdomains and resulting in impaired downstream signaling, ultimately leading to smaller growth cone and elongation failure [51].
PrPC function in the growth cone appears to be dependent, in some instances, on the well-established ability of the protein in binding copper ions. Using focal neurite stimulation, a technology that enables access to the effect of soluble recombinant PrPC molecules released locally in a single growth cone, researchers have described that PrPC can function as a ligand, binding the GPI-anchored form of the protein and initiating a signaling cascade that activates actin remodeling in the periphery of growth cone [55]. More recently, the same research group showed that mutations in distinct copper-binding regions of PrPC impaired neurite outgrowth and growth cone rapid navigation, possibly impacting axonal guidance [56].
The presence of some contrasting evidence on PrPC function for neurite outgrowth is worth noting. A report by Davanathan et al. shows that PrPC may have a negative effect on neurite sprouting through its interaction with Reelin, a glycoprotein with proteolytic activity, and the contactin-associated protein (Caspr), a novel binding partner of PrPC [57]. In this model, PrPC inhibits Reelin’s proteolytic function, protecting Caspr through direct interaction, maintaining its inhibitory effect on neurite growth [57]. These authors argue that this evidence does not contradict previous work that suggests that PrPC influences neurite growth, but rather advocate that PrPC is a regulator of environmental cues of the CNS that balances between neurite outgrowth promotion and inhibition, acting as a positive modulator of this process only in the absence of Caspr activity [57]. A more in-depth study on the signaling behind the observed phenotypes is required to improve the understanding of the proposed role of PrPC in inhibiting neurite sprouting since several different reports have pointed to its role in promoting neurite formation, with strong experimental signaling evidence.
As previously mentioned, interaction with a large number of partner proteins is a relevant aspect of PrPC function, not only in the CNS, but also in other tissues. STI1 is among the best-characterized PrPC ligands. This is a well-described co-chaperone that can be secreted by different cells, including astrocytes, and that binds PrPC extracellularly [58]. PrPC–STI1 interaction protects cells from the toxic effects of staurosporine-induced cell death through Protein kinase A (PKA) signaling and promotes neuritogenesis through the MAPK signaling pathway [59] (Figure 2). It has recently been demonstrated that specific point mutations that disrupt the PrPC–STI1 complex partially or completely impaired neuritogenesis and neuroprotection activity [60], and that STI1 treatment prevented neuronal apoptosis and cell death in a PrPC-dependent manner [61]. Although STI1 is a known PrPC partner, the PrPC–STI1 complex has not been closely studied in the context of cell motility, despite evidence of its importance. Murine STI1 has been shown to strongly and specifically bind F-actin through its TPR2A and TPR2B domains, which interestingly are also PrPC binding sites [62]. Given the high degree of evolutionary conservation of PrPC and STI1, their wide distribution in different cell types and the data gathered here, the PrPC–STI1 complex may regulate processes associated with cell migration, thus requiring further investigation.
Recently, Song and collaborators addressed the role of another possible partner protein, Thymosin Beta 4 (Tβ4), in the deregulation of the cytoskeleton dynamics due to PrPC dysfunction [63]. Tβ4 blocks the polymerization of actin, providing a pool of monomers and functioning on the assembly of the actin filaments [63]. It was observed that Tβ4 mitigates the effects of infection by a PrP amyloidogenic region. Tβ4 treatment increased cell viability, reduced the F-actin/G-actin ratio, and induced the expression of zonula occludens 1 (ZO-1) and occludin, which are proteins found in tight junctions. It is not clear, however, whether Tβ4 acts with PrPC directly, or indirectly through partner proteins [63].
In mammalian brain endothelial cells (BEC), localization of PrPC in cell–cell contacts is dependent on the expression of the protein by two adjacent cells, where it strongly co-localizes with PECAM-1 [35]. PrPC expression increased cell spreading and filopodia formation in Drosophila and N2a cells [64]. Further, PrPC accumulates at the tips of these protrusions, co-localizing with known FA markers, such as phosphorylated-Src and reggie-1. PrPC knockdown (KD) regulates FA dynamics, leading to a reduction in FA number and an increase in FA size [64]. In polarized intestinal epithelial cells, PrPC was preferentially expressed in cell–cell adhesion sites, interacting with actin and Src proteins [65] (Figure 1). Remarkably, PrPC is not only important for the formation of protrusions and cell–cell and cell–matrix contact in nerve cells, but also for other types of cells and tissues.
In zebrafish, PrPC was expressed specifically in sites of trans-homophilic interactions (PrPC–PrPC) [34]. Zebrafish contains the PrP-1 and PrP-2 genes, which are duplicated PrP genes as compared with mammalian PrPC [66]. PrP-1 is ubiquitously expressed at early midblastula stages, while PrP-2 transcripts reach high expression levels in the brain around 30 h post-fertilization [34]. PrP-1 KD in zebrafish embryos resulted in developmental arrest, and this phenotype is explained by the loss of embryonic cell adhesion during gastrulation [34]. Additionally, PrPC KD interfered in the cellular localization of the E-cadherin and β-catenin migration-related proteins and in the disorganization of F-actin in a Ca+2-dependent pathway in different model organisms [34], once more indicating evolutionarily conserved cell adhesion and motility roles. Accordingly, Huc-Brandt and collaborators reported that, during the collective migration process in zebrafish primordium and in neuromast formation, PrP-2 KO results in E-cadherin and β-catenin mislocalization and loss of cell cohesion [67].
In 2011, a study reported the first direct evidence of PrPC modulation in the migration of mouse brain microvascular endothelial cells (BMVEC). A study showed that siRNA downregulation of PrPC resulted in a reduction of approximately 18% in migrating cells compared with controls, covering an area approximately 9% smaller [68].
Both in zebrafish and mammals, one way through which PrPC modulates cell adhesion and controls dynamics of the actin cytoskeleton is by stimulation of Src-related kinases and its targets. In epithelial cells of the digestive tract, PrPC forms AJ with E-cadherin and F-actin while also co-localizing with Src-kinase [36]. In human enterocytes, PrPC interacts with proteins of the Src kinase family, such as Fyn and Src. PrPC activates Fyn through a caveolin-1-dependent coupling [69] and Src through direct physical interaction [36] (Figure 1). Moreover, in human T cells, PrPC can induce reorganization of the actin cytoskeleton through the Src-related kinases Fyn and Lck and increase the levels of intracellular Ca2+ [37]. In zebrafish embryos, PrP-1 buildup at cell contacts elicited similar signaling events [34]. However, in lymphocytes, activated PrPC was found in reggie raft microdomains instead of caveolae [37]. Therefore, the spatial localization of PrPC in microdomains of the plasma membrane might dictate the distribution of Src family signaling partners and consequent activation of different cellular events.
Another way PrPC appears involved with cell–cell adhesion is through interactions with desmosomal proteins, and this has been demonstrated both in enterocytes and BMVEC [70,71]. Intestine from PrPC KO mice and Caco-2/TC7 enterocytes showed increased paracellular permeability and impaired cellular junctions [71]. Cultures from PrPC KD cells exhibited altered morphology and cell junctions, in addition to decreased levels of E-cadherin and the desmosomal proteins desmoplakin, plakoglobin, claudin-4, occludin, ZO-1 and tricellulin at cell contacts [71]. Interestingly, PrPC levels were decreased at cell junctions in epithelia from the colon of patients with Crohn’s disease or ulcerative colitis [71]. In BMVEC, PrPC KD decreased the expression of occludin and claudin-5, leading to augmented permeability in monolayer cultures [70].
PrPC also seems to affect protein interactions in the plasma membrane through the regulation of integrin microclustering and adhesion during monocyte migration. In order to migrate through the endothelium, a process also known as transendothelial migration (TEM) is used, where integrins present in microclusters in the leukocyte plasma membrane bind endothelial ICAM-1 and VCAM-1 receptors, generating strong adhesion to the endothelium [72]. This strong adhesion allows leukocytes to withstand flow-induced detachment and initiate tissue extravasation [72]. This process requires integrins to cluster upon ligand binding, which intensifies avidity and reinforces adhesiveness. Integrin clustering, in its turn, can only occur after its release from the actin cytoskeleton [72,73].
PrPC seems to regulate ligand-induced changes during integrin activation, thus controlling β1-integrin adhesion. PrPC silencing induces cofilin 1 inactivation. This inactivation occurs through phosphorylation on cofilin 1 Ser3 by LIM kinase, which is activated by RhoA [74]. RhoA is able to bind to actin-binding proteins and regulate the assembly of F-actin and the formation of a lamellipodium, a cytoplasmic protrusion involved in cell locomotion [75]. Cofilin 1 severs actin filaments, in addition to depolymerizing F-actin, generating new actin monomers for polymerization [76]. Therefore, in PrPC-deficient cells, the release of activated integrins from the cytoskeleton is prevented, because RhoA-induced cofilin inactivation sustains the stabilization of actin filaments. Ultimately, this hinders integrin microclustering and avidity for its endothelial targets [74]. This is supported by findings of RhoA activation and consequent cofilin inactivation in PrPC-deficient neuronal cells, which increase cytoskeletal stability [77]. In line with this, primary rat hippocampal neurons overexpressing PrPC showed increased cofilin activation and formation of actin-cofilin rods [78], whereas mice overexpressing PrPC showed altered ex vivo thymocyte laminin-induced migration [79].
Moreover, PrPC silencing also altered uropod formation in monocytes possibly by inhibiting phosphorylation of proteins of the ezrin, radixin and moesin (ERM) family. The uropod is a structure with adhesive properties that forms on one edge of the migrating leukocyte during cell polarization. This specialized structure contains cholesterol-rich membrane domains, β1 integrins, and other adhesion receptors, in addition to ERM proteins [80]. In order to migrate, the leukocyte detaches and retracts this uropod, and this process occurs under RhoA control [80]. PrPC silencing alters RhoA activation and reduces ERM phosphorylation with consequent inhibition of uropod formation, since ERM protein activation is essential for this process [74]. As a result, PrPC-deficient monocytes show increased chemotaxis and motility on β1 integrin ligands [74].
In the CNS, there is evidence of possible interactions of PrPC with NCAM1 related to physiological cell motility and migration. PrPC and NCAM seem to bind to each other on the plasma membrane, and NCAM could be one of the transmembrane factors linking PrPC and Fyn on N2a cells, since they lack expression of caveolin-1 [81]. NCAM and the L1 cell adhesion molecule (L1-CAM) also take part in neurite outgrowth. More specifically, some members of the Ig superfamily of CAMs can activate important pathways through FGFR receptors and PTKs of the Scr family, leading to tyrosine phosphorylation and thereby assisting in growth cone guidance [82]. Moreover, it has been demonstrated that PrPC and NCAM1 interaction leads to the recruitment of Fyn to lipid rafts and stimulates outgrowth of neurites (Figure 2). This interaction has also been observed in the mouse brain [83], N2a cells [84], and rat cerebellar granule cells [85].
Another role played by this PrPC–NCAM1 interaction was revealed for epithelial–mesenchymal transition (EMT). In EMT, epithelial cells develop features of mesenchymal cells towards a migratory phenotype, thus losing cell–cell adhesion structures and polarity [86]. It has been demonstrated that NCAM1 undergoes polysialylation during EMT, and this is hindered by PrPC deficiency [87]. Moreover, this perturbation was caused by decreased transcription of the polysialyltransferase gene ST8SIA2, possibly through transcriptional regulation by β-catenin [87].
Furthermore, the redistribution of NCAM1 and recruitment to caveolae or raft-like domains is an early step of EMT during gastrulation of human embryonic stem cells. This occurs concomitantly with stimulation of p59Fyn (from the Src family kinase), activation of FAK, and the association of integrin-mediated FA [88]. In PrPC-1-deficient zebrafish embryos, blastodermal margin cells showed slower migration, while PrPC-1-deficient blastomeres showed impaired ability to re-establish cellular contacts. PrPC-1 in normal zebrafish embryos, however, increased p59Fyn at cell contacts, in addition to modulating E-cadherin through regulation of its dynamics from intracellular stores to the plasma membrane. It is noteworthy that this altered phenotype of PrPC-1-deficient zebrafish embryos was rescued with the introduction of mammalian PrPC [34].
Moreover, expression of PrPC and NCAM1 increases substantially during early EMT induction in mice. In the same model, PrPC increased NCAM1 polysialysation during EMT via modulation of ST8SIA2 transcription [87].
Thus, the physiological roles of PrPC in cell migration seem to occur through direct binding to its targets or via indirect activation of signaling kinases. Hitherto, the main players described in PrPC-mediated cell adhesion are those related to Src kinases and adhesion proteins in the plasma membrane, and β-catenin in the cytosol and nucleus, regulating gene expression. Finding novel PrPC-collaborating molecules or even attributing new roles to known important partners in the modulation of cellular motility, such as STI1, can bring important information for understanding this process, not only in the physiological context, but especially the contribution of PrPC in pathological processes such as tumor cell migration, which are addressed in the following section.

3. Cellular Prion Protein in Cancer Cell Motility

Cell motility mechanisms are quite relevant for cancer survival and are orchestrated by a variety of molecules, including prion protein. The processes of invasion and metastasis allow cancer cells to spread throughout tissues [89], which hinders surgical resections and therapy [90,91,92]. These malignant behaviors are associated with poor prognoses and higher recurrence rates of several cancer types, such as colorectal adenocarcinoma [93], glioblastoma [94], metastatic gastric cancer [95], and melanoma [96]. Strikingly, metastases have been linked to approximately 90% of cancer-related deaths [89]. Tumor resection is a common approach in cancer treatment [97,98,99,100], although data from the literature demonstrate that attempting to resect a tumor may contribute to recurrence and to the cancer capability of forming metastases [101,102]. Concerning these issues, many studies have been focusing on understanding the motility mechanisms of cancer cells and molecules that may be involved in these processes.
Cancer cells can migrate and invade adjacent tissues, and the expression and secretion of proteins related to cell–cell adhesion and ECM degradation are crucial to the invasion and metastasis development during malignant cancers [103]. Invasion occurs when cells penetrate the surrounding tissue, or stroma, through the extracellular matrix and cell–cell interactions [103]. Once these cells cross the basement membranes, they can progress to intravasation of vessels, into the vascular or lymphatic circulation, characterizing the beginning of metastasis. In the next step, the extravasation into the lumen of the vessels of the circulatory system lead cancer cells to establish new tumors (micrometastasis) in any other tissue or organ in the body, generating new secondary and tertiary tumors (colonization) [104].
Mechanisms of invasion and metastasis are closely related and use similar strategies of protein interactions and secretion of proteases, both being considered as a unique hallmark of cancer [105]. These proteins include CAMs such as those from the cadherin and integrin families, which are responsible for ECM interactions [105]. For example, E-cadherin can modulate cell–cell interaction through β-catenin modulation and, in many cancers, the loss of E-cadherin expression promotes invasion and metastasis, which can be associated with EMT processes [104,106,107,108]. On the other hand, N-cadherin expression is increased in several tumors [104,109]. NCAM is another example of a molecule whose expression is related to invasion and metastasis of some types of neoplasms [105,110]. Furthermore, there are many subtypes of integrins expressed in several cancer cells, especially in carcinomas. They can shift the types of integrins expressed on the cell surface according to the ECM, thus facilitating migration and, consequently, invasion and metastasis [105,111]. Additionally, with adhesion molecules, expression of extracellular proteases is crucial to degrade components in ECM to facilitate motility, which can be expressed not only by cancer cells, but also by stroma and inflammatory cells present in the surrounding tissue [105,112]. Indeed, this crosstalk between tumor cells and stroma is extremely important for tumor invasion–metastasis cascades. For example, mesenchymal stem cells can secrete factors that increase invasion and macrophages can secrete matrix-degrading proteases as metalloproteinases, facilitating the intravasation to circulatory vessels [104,113,114,115].
Briefly, the tumor microenvironment is rich in cell–cell and cell–ECM interactions, leading to a close relationship between components in these niches. As such, they work together to facilitate cell migration, promoting invasion and metastatic processes and, consequently, cancer progression.
PrPC has been implicated in the cell motility of several cancer types, including colon and colorectal cancer. Some cells within colorectal carcinoma express PrPC and are spread across the parenchyma of the tumor, albeit they are concentrated mainly in the invasive front of cancer [116], which, in this case, is the region where the majority of EMT occurs [116]. Consistently, it has been shown that PrPC induces EMT in colon adenocarcinoma and colorectal carcinoma cell lines, modulating protein expression levels of E-cadherin and N-cadherin as well as the translocation of β-catenin [116]. Moreover, PrPC is also involved in the metastatic potential of these cells, because it triggers the Fyn-SP1-SATB1 pathway to promote metastasis [116]. Remarkably, the normal tissue that surrounds colorectal carcinoma shows low PrPC expression compared with the cancerous tissue [116]. Additionally, in colorectal adenocarcinoma cell lines, PrPC interaction with STI1 was related to cell migration and invasion by activating ERK1/2 signaling [93]. Data from the literature have demonstrated that some colorectal cancer lineages exhibit a subpopulation of cancer stem cells that express PrPC and are positive for the stem cell marker CD44 [117]. In these cancer stem cells, the transcription factor Twist acts downstream of PrPC and mediates EMT [117]. Furthermore, it has been demonstrated that PrPC interacts with the ECM protein laminin, leading to activation of the MAPK cascade and induction of EMT [117]. In PrPC-overexpressing colon cancer cell lines, it was observed that this protein is involved in cell adhesion to fibronectin and collagen in the ECM [118]. Moreover, PrPC augments both the growth and the motility of these cancer cells [118].
Besides colon and colorectal cancer, PrPC also plays important roles in the motility of pancreatic cancer cells. Normal pancreatic tissues do not express PrPC, whereas pancreatic ductal adenocarcinoma (PDAC) cell lines express an alternative form of PrPC—the so-called pro-PrPC, which retains a GPI-anchor peptide signal sequence that crosses the plasma membrane [119,120,121]. In these PDAC cell lineages, this modification enables PrPC to interact with certain molecules such as filamin A (FLNa) [119,120,121] and Notch1 [119], forming multiprotein complexes on the cellular membranes [119]. The interaction between PrPC and Notch1 upregulates the latter, stimulating cell growth and invasion [119]. Importantly, PrPC expression is directly associated with the invasive capacity of this pancreatic cancer [121]. Yet, the interactivity between PrPC and FLNa has implications on the motility of PDAC cell lines [120].
In melanoma, PrPC also exists in the pro-PrPC form, and in FLNa deficient melanoma cell lines, modulations in the PRNP gene expression affect cell migration [122]. In addition, PrPC modulates actin polymerization through Akt and HSP27 [122].
PrPC has also been associated with the invasive and metastatic processes of gastric cancer. PrPC is highly expressed in metastatic gastric cancer and it has been observed that this protein contributes to the adhesive capability of gastric cancer cell lines [123]. In addition, it has also been shown that PrPC plays a role in gastric cancer invasion through the ERK1/2 pathway [29,123], as well as in MMP11 expression at both mRNA and protein levels [123]. Concerning the ability of the gastric tumor to metastasize, PrPC is related to gastric cancer metastasis to the liver [123] and lymph nodes [124].
Regarding lung cancer, the PRNP gene is upregulated by NFIL3 in invasive lung adenocarcinoma (ILA) cell lines [90] and, at the protein level, PrPC expression is widely observed in invasive tumors, but not in in situ tumors [90]. Furthermore, lamellipodia regions of ILA cell lines show augmented PrPC expression, and this protein modulates the levels of active Rac1 and the migration of these cells [90]. PrPC has been implicated in the metastatic capability of ILA in in vivo assays, and PrPC interaction with the JNK pathway induces the motility of ILA cell lines [90]. In addition, NFIL3 and PrPC act towards cancer cell migration [90].
In breast cancer cell lines, PrPC-overexpressing cells demonstrated an intensified ability to migrate and invade, without alterations in cancer cell proliferation [124]. Furthermore, it has been shown that a higher expression of PrPC upregulates MMP9 at mRNA levels and, consequently, protein levels, by triggering the NF-κB and ERK pathways, which may contribute to the motility of this cancer [124]. Moreover, multidrug-resistant breast cancer cell lines show increased PrPC and CD44 expressions and interactivity between them, with the latter modulating PrPC [125]. In addition, the interaction held by these two proteins is involved in cell migration mechanisms through the EGFR, CD147, MMP2 and MMP9 proteins, which act as downstream effectors [125].
Among gliomas, glioblastoma multiforme (GBM) is a highly invasive and aggressive tumor [94] that presents PrPC upregulation [33]. It has been demonstrated that PrPC may be involved in the recruitment of E-cadherin to the plasma membrane of GBM stem cells (GSCs) and, in addition, PrPC was shown to influence the localization of β-catenin [31]. Additionally, PrPC was associated with the adhesion and mobility of GSCs, given that changes in PrPC expression affect the migration of these cells on laminin as well as the expression of integrin α6 [31].
In neuroblastoma cell lines, expression of PrPC is involved in cell aggregation and PrPC-mediated cell adhesion does not depend on cations [126].
Interestingly, whereas some non-neoplastic tissues present low PrPC expression, this protein is upregulated in cancer tissue samples [116,119]. Moreover, PrPC also shows higher expression in invasive and metastatic cancers compared with non-invasive and non-metastatic ones [90,123].
In summary, these data support an important role for PrPC in cell motility processes of several cancer types, since PrPC has been widely shown to be related to cancer cell migration, invasion and metastasis, being involved in the recruitment of molecules and signaling platforms, in the modulation of the expression of genes and proteins, and in the activation of intracellular pathways in tumor cells (Table 1). Finally, these data point to PrPC as a potential target for cancer treatments, given that its targeting may reduce the malignant behavior of several tumors.

4. Perspectives and Conclusions

Cell motility is an important process to the development, maintenance and healing of all tissues, and is essential for the normal functioning of the body. These processes require the transient formation of multiprotein complexes to modulate different signaling cascades which, together, lead to a close-fitting regulation of cellular and molecular phenotypes. As a scaffold protein, PrPC functions as a promiscuous molecule that is able to interact with several partners and, as discussed throughout this review, orchestrates many signaling pathways involved with cell motility. This PrPC scaffolding property might favor protein recruitment and higher-order assemblies into a dynamic molecular platform on the plasma membrane and provide an efficient and reversible mechanism to control intercellular signaling pathways.
The seemingly controversial roles of PrPC, such as neurite growth, axon guidance and leukocyte migration, could be explained by the dependence of PrPC on the cell context. For instance, despite the reports supporting PrPC function in neurite sprouting, a mechanism proposed in 2010 shows that, depending on the specific binding partner of PrPC on the cell membrane, it may or may not influence protrusion formation in growth cones [57]. These findings highlight even further the role of PrPC as a sensor of environmental cues, functioning as a key molecule in dynamic control of molecular platforms, in the CNS and other tissues, as well as in health and disease, to trigger different outcomes for the cell.
Although PrPC partners are mostly the same in different tissues—β1-integrin and Src kinases, for example—the balance between upregulated and downregulated signaling pathways will ultimately dictate the function of PrPC in the cell at a given context. In several processes described in this review, however, there are still gaps of knowledge and unknown binding partners of PrPC to explain its effects on cell motility. Thus, the characterization of novel ligands assigned to signaling propagation of PrPC scaffolding platform is of utmost importance to understand PrPC physiological role during cell movement.
In addition, PrPC can also be co-opted by tumoral cells to ensure their survival. Through cell motility processes, tumor cells are capable of invading and metastasizing to other organs and, although the exact percentage is still a debate, a recent study concluded that metastasis could be responsible for more than 65% of cancer deaths [127], while others claim it could be as high as 90% [89]. PrPC expression is upregulated in several types of invasive and metastatic cancers [90,123]. Thus, an intriguing parallel can be established between PrPC physiological and cancer-related functions. While preferential localization of PrPC in specific membrane microdomains favors its interaction with Fyn, supporting proper axon guidance [51], actin cytoskeleton reorganization [37], and N-cadherin transport in the plasma membrane [53], PrPC is also involved in the promotion of metastasis through Fyn activation [116]. Additionally, F-actin and PrPC bind STI1 through the same domain [62], and several lines of evidence point to the promotion of neuroprotection through PrPC–STI1 interaction [59,60,61], while the same interaction was associated to cancer cell migration and invasion through ERK1/2 activation [93]. These are some of the examples of physiological PrPC-binding preferences that cancer cells might hijack to improve tumor maintenance, invasion and migration.
Furthermore, as discussed in this review, cancer cells appear to take advantage of the PrPC role in cell motility through its binding to N-cadherin and E-cadherin to promote EMT and increase tumor invasion and aggressiveness. In the context of increased survival and proliferation seen in cancer cells, the PrPC function in cell motility seems to be enhanced. Moreover, with the PrPC scaffolding properties facilitating cell signaling, cancer cells are able to invade and spread. Given the functional plasticity of PrPC and its scaffold feature, a deep understanding of its role in the organization and activity of higher-order molecular modules on the cell membrane, in the context of space and time, is imperative to unveil its function as a signaling organizer. Finally, these data demonstrate the importance of uncovering PrPC partners and unveiling their role in motility-related processes, as well as the impact of this molecule as a target for the development of new and effective therapies against metastatic cancer.

Author Contributions

Review conceptualization M.B.P. and M.H.L.; writing M.B.P., M.I.M.E., R.N.A., B.P.C., C.F.d.L.F., J.M.B. and R.P.I.; reviewing and editing M.B.P., M.I.M.E., R.N.A., B.P.C., C.F.d.L.F., J.M.B., R.P.I. and M.H.L.; figure conceptualization M.B.P. and B.P.C.; figure design M.I.M.E.; table conceptualization and design M.B.P. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, Processes numbers: M.B.P.: 2017/26158-0; M.I.M.E.: 2019/11097-1; R.N.A.: 2020/04687-4; B.P.C.: 2019/14952-0; C.F.d.L.F.: 2019/14741-9; J.M.B.: 2020/07450-5; R.P.I.: 2019/12710-9; M.H.L.: 2018/15557-4;) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, Process number: J.M.B.: 101796/2020-0).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Hohmann, T.; Dehghani, F. The Cytoskeleton—A Complex Interacting Meshwork. Cells 2019, 8, 362. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Aman, A.; Piotrowski, T. Cell migration during morphogenesis. Dev. Biol. 2010, 341, 20–33. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Lamalice, L.; Le Boeuf, F.; Huot, J. Endothelial cell migration during angiogenesis. Circ. Res. 2007, 100, 782–794. [Google Scholar] [CrossRef] [PubMed]
  4. Gerthoffer, W.T. Mechanisms of vascular smooth muscle cell migration. Circ. Res. 2007, 100, 607–621. [Google Scholar] [CrossRef] [Green Version]
  5. Cramer, L.P.; Mitchison, T.J.; Theriot, J.A. Actin-dependent motile forces and cell motility. Curr. Opin. Cell Biol. 1994, 6, 82–86. [Google Scholar] [CrossRef]
  6. Krawczyk, W.S. A pattern of epidermal cell migration during wound healing. J. Cell Biol. 1971, 49, 247–263. [Google Scholar] [CrossRef] [Green Version]
  7. Ananthakrishnan, R.; Ehrlicher, A. The Forces Behind Cell Movement. Int. J. Biol. Sci. 2007, 3, 303–317. [Google Scholar] [CrossRef]
  8. Stricker, J.; Falzone, T.; Gardel, M.L. Mechanics of the F-actin cytoskeleton. J. Biomech. 2010, 43, 9–14. [Google Scholar] [CrossRef] [Green Version]
  9. Nelson, W.J. Adaptation of core mechanisms to generate cell polarity. Nature 2003, 422, 766–774. [Google Scholar] [CrossRef]
  10. Trepat, X.; Chen, Z.; Jacobson, K. Cell migration. Compr. Physiol. 2012, 2, 2369–2392. [Google Scholar]
  11. Carnell, M.J.; Insall, R.H. Actin on disease - Studying the pathobiology of cell motility using Dictyostelium discoideum. Semin. Cell Dev. Biol. 2011, 22, 82–88. [Google Scholar] [CrossRef] [PubMed]
  12. Thiery, J.P.; Acloque, H.; Huang, R.Y.J.; Nieto, M.A. Epithelial-Mesenchymal Transitions in Development and Disease. Cell 2009, 139, 871–890. [Google Scholar] [CrossRef] [PubMed]
  13. Manson, J.; West, J.D.; Thomson, V.; McBride, P.; Kaufman, M.H.; Hope, J. The prion protein gene: A role in mouse embryogenesis? Development 1992, 115, 117–122. [Google Scholar] [PubMed]
  14. Lopes, M.H.; Santos, T.G. Prion potency in stem cells biology. Prion 2012, 6, 142–146. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Hartmann, C.A.; Martins, V.R.; Lima, F.R.S. High levels of Cellular Prion Protein improve astrocyte development. FEBS Lett. 2013, 587, 238–244. [Google Scholar] [CrossRef] [PubMed]
  16. Bribián, A.; Fontana, X.; Llorens, F.; Gavín, R.; Reina, M.; García-Verdugo, J.M.; Torres, J.M.; de Castro, F.; del Río, J.A. Role of the cellular prion protein in oligodendrocyte precursor cell proliferation and differentiation in the developing and adult mouse CNS. PLoS ONE 2012, 7. [Google Scholar]
  17. Adle-Biassette, H.; Verney, C.; Peoc’h, K.; Dauge, M.C.; Razavi, F.; Choudat, L.; Gressens, P.; Budka, H.; Henin, D. Immunohistochemical expression of prion protein (PrPC) in the human forebrain during development. J. Neuropathol. Exp. Neurol. 2006, 65, 698–706. [Google Scholar] [CrossRef] [Green Version]
  18. Glatzel, M.; Aguzzi, A. PrP(C) expression in the peripheral nervous system is a determinant of prion neuroinvasion. J. Gen. Virol. 2000, 81, 2813–2821. [Google Scholar] [CrossRef]
  19. Peralta, O.A.; Eyestone, W.H. Quantitative and qualitative analysis of cellular prion protein (PrP C) expression in bovine somatic tissues. Prion 2009, 3, 161–170. [Google Scholar] [CrossRef] [Green Version]
  20. Stahl, N.; Baldwin, M.A.; Hecker, R.; Pan, K.M.; Burlingame, A.L.; Prusiner, S.B. Glycosylinositol Phospholipid Anchors of the Scrapie and Cellular Prion Proteins Contain Sialic Acid. Biochemistry 1992, 31, 5043–5053. [Google Scholar] [CrossRef]
  21. Riek, R.; Hornemann, S.; Wider, G.; Billeter, M.; Glockshuber, R.; Wüthrich, K. NMR structure of the mouse prion protein domain PrP(121-231). Nature 1994. [Google Scholar] [CrossRef] [PubMed]
  22. Haire, L.F.; Whyte, S.M.; Vasisht, N.; Gill, A.C.; Verma, C.; Dodson, E.J.; Dodson, G.G.; Bayley, P.M. The Crystal Structure of the Globular Domain of Sheep Prion Protein. J. Mol. Biol. 2004, 336, 1175–1183. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Taubner, L.M.; Bienkiewicz, E.A.; Copié, V.; Caughey, B. Structure of the flexible amino-terminal domain of prion protein bound to a sulfated glycan. J. Mol. Biol. 2010, 395, 475–490. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Smith, C.J.; Drake, A.F.; Banfield, B.A.; Bloomberg, G.B.; Palmer, M.S.; Clarke, A.R.; Collinge, J. Conformational properties of the prion octa-repeat and hydrophobic sequences. FEBS Lett. 1997, 405, 378–384. [Google Scholar] [CrossRef]
  25. Slapšak, U.; Salzano, G.; Amin, L.; Abskharon, R.N.N.; Ilc, G.; Zupančič, B.; Biljan, I.; Plavec, J.; Giachin, G.; Legname, G. The N terminus of the prion protein mediates functional interactions with the neuronal cell adhesion molecule (NCAM) fibronectin domain. J. Biol. Chem. 2016, 291, 21857–21868. [Google Scholar] [CrossRef] [Green Version]
  26. Ulbrich, S.; Janning, P.; Seidel, R.; Matschke, J.; Gonsberg, A.; Jung, S.; Glatzel, M.; Engelhard, M.; Winklhofer, K.F.; Tatzelt, J. Alterations in the brain interactome of the intrinsically disordered N-terminal domain of the cellular prion protein (PrPC) in Alzheimer’s disease. PLoS ONE 2018, 13, 1–15. [Google Scholar] [CrossRef]
  27. Didonna, A. Prion protein and its role in signal transduction. Cell. Mol. Biol. Lett. 2013, 18, 209–230. [Google Scholar] [CrossRef]
  28. Martellucci, S.; Santacroce, C.; Santilli, F.; Manganelli, V.; Sorice, M.; Mattei, V. Prion protein in stem cells: A lipid raft component involved in the cellular differentiation process. Int. J. Mol. Sci. 2020, 21, 4168. [Google Scholar] [CrossRef]
  29. Santos, T.G.; Lopes, M.H.; Martins, V.R. Targeting prion protein interactions in cancer. Prion 2015, 9, 165–173. [Google Scholar] [CrossRef]
  30. Martins, V.R.; Beraldo, F.H.; Hajj, G.N.; Lopes, M.H.; Lee, K.S.; Prado, M.A.; Linden, R. Prion protein: Orchestrating neurotrophic activities. Curr. Issues Mol. Biol. 2010, 12, 63–86. [Google Scholar]
  31. Iglesia, R.P.; Prado, M.B.; Cruz, L.; Martins, V.R.; Santos, T.G.; Lopes, M.H. Engagement of cellular prion protein with the co-chaperone Hsp70/90 organizing protein regulates the proliferation of glioblastoma stem-like cells. Stem Cell Res. Ther. 2017, 8, 1–14. [Google Scholar] [CrossRef] [PubMed]
  32. Santos, T.G.; Silva, I.R.; Costa-Silva, B.; Lepique, A.P.; Martins, V.R.; Lopes, M.H. Enhanced neural progenitor/stem cells self-renewal via the interaction of stress-inducible protein 1 with the prion protein. Stem Cells 2011, 29, 1126–1136. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Lopes, M.H.; Santos, T.G.; Rodrigues, B.R.; Queiroz-Hazarbassanov, N.; Cunha, I.W.; Wasilewska-Sampaio, A.P.; Costa-Silva, B.; Marchi, F.A.; Bleggi-Torres, L.F.; Sanematsu, P.I.; et al. Disruption of prion protein-HOP engagement impairs glioblastoma growth and cognitive decline and improves overall survival. Oncogene 2015, 34, 3305–3314. [Google Scholar] [CrossRef] [PubMed]
  34. Málaga-Trillo, E.; Solis, G.P.; Schrock, Y.; Geiss, C.; Luncz, L.; Thomanetz, V.; Stuermer, C.A.O. Regulation of Embryonic Cell Adhesion by the Prion Protein. PLoS ONE 2009, 7, 576–590. [Google Scholar]
  35. Viegas, P.; Chaverot, N.; Enslen, H.; Perrière, N.; Couraud, P.O.; Cazaubon, S. Junctional expression of the prion protein PrPC by brain endothelial cells: A role in trans-endothelial migration of human monocytes. J. Cell Sci. 2006, 119, 4634–4643. [Google Scholar] [CrossRef] [Green Version]
  36. Morel, E.; Fouquet, S.; Chateau, D.; Yvernault, L.; Frobert, Y.; Pinçon-Raymond, M.; Chambaz, J.; Pillot, T.; Rousset, M. The Cellular Prion Protein PrPc Is Expressed in Human Enterocytes in Cell-Cell Junctional Domains. J. Biol. Chem. 2004, 279, 1499–1505. [Google Scholar] [CrossRef] [Green Version]
  37. Stuermer, C.A.O.; Langhorst, M.F.; Wiechers, M.F.; Legler, D.F.; von Hanwehr, S.H.; Guse, A.H.; Plattner, H. PrPC capping in T cells promotes its association with the lipid raft proteins reggie-1 and reggie-2 and leads to signal transduction. FASEB J. 2004, 18, 1731–1733. [Google Scholar] [CrossRef] [Green Version]
  38. Bremer, J.; Baumann, F.; Tiberi, C.; Wessig, C.; Fischer, H.; Schwarz, P.; Steele, A.D.; Toyka, K.V.; Nave, K.A.; Weis, J.; et al. Axonal prion protein is required for peripheral myelin maintenance. Nat. Neurosci. 2010, 13, 310–318. [Google Scholar] [CrossRef]
  39. Nuvolone, M.; Hermann, M.; Sorce, S.; Russo, G.; Tiberi, C.; Schwarz, P.; Minikel, E.; Sanoudou, D.; Pelczar, P.; Aguzzi, A. Strictly co-isogenic C57BL/6J-Prnp-/- mice: A rigorous resource for prion science. J. Exp. Med. 2016, 213, 313–327. [Google Scholar] [CrossRef] [Green Version]
  40. Tanaka, A.; Fujii, Y.; Kasai, N.; Okajima, T.; Nakashima, H. Regulation of neuritogenesis in hippocampal neurons using stiffness of extracellular microenvironment. PLoS ONE 2018, 13, 1–16. [Google Scholar] [CrossRef] [Green Version]
  41. Wulf, M.A.; Senatore, A.; Aguzzi, A. The biological function of the cellular prion protein: An update. BMC Biol. 2017, 15, 1–13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Lee, J.; Song, K.H.; Kim, T.; Doh, J. Endothelial cell focal adhesion regulates transendothelial migration and subendothelial crawling of T cells. Front. Immunol. 2018, 9, 1–9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Loubet, D.; Dakowski, C.; Pietri, M.; Pradines, E.; Bernard, S.; Callebert, J.; Ardila-Osorio, H.; Mouillet-Richard, S.; Launay, J.; Kellermann, O.; et al. Neuritogenesis: The prion protein controls β1 integrin signaling activity. FASEB J. 2012, 26, 678–690. [Google Scholar] [CrossRef] [PubMed]
  44. Huveneers, S.; Danen, E.H.J. Adhesion signaling - Crosstalk between integrins, Src and Rho. J. Cell Sci. 2009, 122, 1059–1069. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Katoh, K. Activation of Rho-kinase and focal adhesion kinase regulates the organization of stress fibers and focal adhesions in the central part of fibroblasts. PeerJ 2017, 2017. [Google Scholar] [CrossRef] [PubMed]
  46. Meldolesi, J. Neurite outgrowth: This process, first discovered by Santiago Ramon y Cajal, is sustained by the exocytosis of two distinct types of vesicles. Brain Res. Rev. 2011, 66, 246–255. [Google Scholar] [CrossRef]
  47. Kahn, O.I.; Baas, P.W. Microtubules and Growth Cones: Motors Drive the Turn. Trends Neurosci. 2016, 176, 100–106. [Google Scholar] [CrossRef] [Green Version]
  48. Omotade, O.F.; Pollitt, S.L.; Zheng, J.Q. Actin-based growth cone motility and guidance. Mol. Cell. Neurosci. 2017, 84, 4–10. [Google Scholar] [CrossRef]
  49. Kohtaro, M.; Emmerling, K.; Manuelidis, L. Proliferative arrest of neural cells induces prion protein synthesis, nanotube formation and cell-to-cell contacts. J Cell Biochem. 2014, 23, 1–7. [Google Scholar]
  50. Bueler, H.; Fischer, M.; Lang, Y.; Bluethmann, H.; Lippt, H.; Dearmond, S.J.; Prusiner, S.B.; Aguet, M.; Weissmann, C. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 1992, 356, 577–582. [Google Scholar] [CrossRef]
  51. Bodrikov, V.; Solis, G.P.; Stuermer, C.A.O. Prion protein promotes growth cone development through reggie/flotillin-dependent N-cadherin trafficking. J. Neurosci. 2011, 31, 18013–18025. [Google Scholar] [CrossRef] [PubMed]
  52. Solis, G.P.; Malaga-Trillo, E.; Plattner, H.; Stuermer, C.A.O. Cellular roles of the prion protein in association with reggie/flotillin microdomains. Front. Biosci. 2010, 15, 1075–1085. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Stuermer, C.A.O. How reggies regulate regeneration and axon growth. Cell Tissue Res. 2012, 349, 71–77. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Gomez, T.M.; Robles, E.; Poo, M.M.; Spitzer, N.C. Filopodial calcium transients promote substrate-dependent growth cone turning. Science (80-. ). 2001, 291, 1983–1987. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Amin, L.; Nguyen, X.T.A.; Rolle, I.G.; D’Este, E.; Giachin, G.; Tran, T.H.; Šerbec, V.Č.; Cojoc, D.; Legname, G. Characterization of prion protein function by focal neurite stimulation. J. Cell Sci. 2016, 129, 3878–3891. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  56. Nguyen, X.T.A.; Tran, T.H.; Cojoc, D.; Legname, G. Copper Binding Regulates Cellular Prion Protein Function. Mol. Neurobiol. 2019, 56, 6121–6133. [Google Scholar] [CrossRef] [PubMed]
  57. Devanathan, V.; Jakovcevski, I.; Santuccione, A.; Li, S.; Lee, H.J.; Peles, E.; Leshchyns’ka, I.; Sytnyk, V.; Schachner, M. Cellular form of prion protein inhibits reelin-mediated shedding of Caspr from the neuronal cell surface to potentiate Caspr-mediated inhibition of neurite outgrowth. J. Neurosci. 2010, 30, 9292–9305. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  58. Zanata, S.M.; Lopes, M.H.; Mercadante, A.F.; Hajj, G.N.M.; Chiarini, L.B.; Nomizo, R.; Freitas, A.R.O.; Cabral, A.L.B.; Lee, K.S.; Juliano, M.A.; et al. Stress-inducible protein 1 is a cell surface ligand for cellular prion that triggers neuroprotection. Embo J. 2002, 21, 3307–3316. [Google Scholar] [CrossRef]
  59. Lopes, M.H.; Hajj, G.N.M.; Muras, A.G.; Mancini, G.L.; Castro, R.M.P.S.; Ribeiro, K.C.B.; Brentani, R.R.; Linden, R.; Martins, V.R. Interaction of cellular prion and stress-inducible protein 1 promotes neuritogenesis and neuroprotection by distinct signaling pathways. J. Neurosci. 2005, 25, 11330–11339. [Google Scholar] [CrossRef] [Green Version]
  60. Beraldo, F.H.; Ostapchenko, V.G.; Xu, J.Z.; Di Guglielmo, G.M.; Fan, J.; Nicholls, P.J.; Caron, M.G.; Prado, V.F.; Prado, M.A.M. Mechanisms of neuroprotection against ischemic insult by stress-inducible phosphoprotein-1/prion protein complex. J. Neurochem. 2018, 145, 68–79. [Google Scholar] [CrossRef] [Green Version]
  61. Landemberger, M.C.; de Oliveira, G.P.; Machado, C.F.; Gollob, K.J.; Martins, V.R. Loss of STI1-mediated neuronal survival and differentiation in disease-associated mutations of prion protein. J. Neurochem. 2018, 145, 409–416. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  62. Beckley, S.J.; Hunter, M.C.; Kituyi, S.N.; Wingate, I.; Chakraborty, A.; Schwarz, K.; Makhubu, M.P.; Rousseau, R.P.; Ruck, D.K.; de la Mare, J.A.; et al. STIP1/HOP regulates the actin cytoskeleton through interactions with actin and changes in actin-binding proteins cofilin and profilin. Int. J. Mol. Sci. 2020, 21, 3152. [Google Scholar] [CrossRef] [PubMed]
  63. Song, K.; Han, H.J.; Kim, S.; Kwon, J. Thymosin beta 4 attenuates PrP(106-126)-induced human brain endothelial cells dysfunction. Eur. J. Pharmacol. 2020, 869, 172891. [Google Scholar] [CrossRef] [PubMed]
  64. Schrock, Y.; Solis, G.P.; Stuermer, C.A.O. Regulation of focal adhesion formation and filopodia extension by the cellular prion protein (PrPC). FEBS Lett. 2009, 583, 389–393. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Morel, E.; Fouquet, S.; Strup-Perrot, C.; Thievend, C.P.; Petit, C.; Loew, D.; Faussat, A.M.; Yvernault, L.; Pinçon-Raymond, M.; Chambaz, J.; et al. The cellular prion protein PrPc is involved in the proliferation of epithelial cells and in the distribution of junction-associated proteins. PLoS ONE 2008, 3. [Google Scholar] [CrossRef]
  66. Rivera-Milla, E.; Oidtmann, B.; Panagiotidis, C.H.; Baier, M.; Sklaviadis, T.; Hoffmann, R.; Zhou, Y.; Solis, G.P.; Stuermer, C.A.O.; Málaga-Trillo, E. Disparate evolution of prion protein domains and the distinct origin of Doppel- and prion-related loci revealed by fish-to-mammal comparisons. FASEB J. 2006, 20, 317–319. [Google Scholar] [CrossRef] [Green Version]
  67. Huc-Brandt, S.; Hieu, N.; Imberdis, T.; Cubedo, N.; Silhol, M.; Leighton, P.L.A.; Domaschke, T.; Allison, W.T.; Perrier, V.; Rossel, M. Zebrafish prion protein PrP2 controls collective migration process during lateral line sensory system development. PLoS ONE 2014, 9, 1–22. [Google Scholar] [CrossRef] [Green Version]
  68. Watanabe, T.; Yasutaka, Y.; Nishioku, T.; Kusakabe, S.; Futagami, K.; Yamauchi, A.; Kataoka, Y. Involvement of the cellular prion protein in the migration of brain microvascular endothelial cells. Neurosci. Lett. 2011, 496, 121–124. [Google Scholar] [CrossRef]
  69. Mouillet-Richard, S.; Ermonval, M.; Chebassier, C.; Laplanche, J.L.; Lehmann, S.; Launay, J.M.; Kellermann, O. Signal transduction through prion protein. Science (80-. ). 2000, 289, 1925–1928. [Google Scholar] [CrossRef] [Green Version]
  70. Megra, B.W.; Eugenin, E.A.; Berman, J.W. Inflammatory mediators reduce surface PrPc on human BMVEC resulting in decreased barrier integrity. Lab Invest. 2017, 176, 139–148. [Google Scholar] [CrossRef]
  71. Petit, C.S.V.; Barreau, F.; Besnier, L.; Gandille, P.; Riveau, B.; Chateau, D.; Roy, M.; Berrebi, D.; Svrcek, M.; Cardot, P.; et al. Requirement of cellular prion protein for intestinal barrier function and mislocalization in patients with inflammatory bowel disease. Gastroenterology 2012, 143, 122–132.e15. [Google Scholar] [CrossRef] [PubMed]
  72. Alon, R.; Feigelson, S.W.; Manevich, E.; Rose, D.M.; Schmitz, J.; Overby, D.R.; Winter, E.; Grabovsky, V.; Shinder, V.; Matthews, B.D.; et al. A4Β1-Dependent Adhesion Strengthening Under Mechanical Strain Is Regulated By Paxillin Association With the A4-Cytoplasmic Domain. J. Cell Biol. 2005, 171, 1073–1084. [Google Scholar] [CrossRef] [PubMed]
  73. Nourshargh, S.; Hordijk, P.L.; Sixt, M. Breaching multiple barriers: Leukocyte motility through venular walls and the interstitium. Nat. Rev. Mol. Cell Biol. 2010, 11, 366–378. [Google Scholar] [CrossRef] [PubMed]
  74. Richardson, D.D.; Tol, S.; Valle-Encinas, E.; Pleguezuelos, C.; Bierings, R.; Geerts, D.; Fernandez-Borja, M. The prion protein inhibits monocytic cell migration by stimulating β1 integrin adhesion and uropod formation. J. Cell Sci. 2015, 128, 3018–3029. [Google Scholar] [CrossRef] [Green Version]
  75. Ridley, A.J. Rho GTPase signalling in cell migration. Curr. Opin. Cell Biol. 2015, 36, 103–112. [Google Scholar] [CrossRef] [Green Version]
  76. Wioland, H.; Guichard, B.; Senju, Y.; Myram, S.; Lappalainen, P.; Jégou, A.; Romet-Lemonne, G. ADF/Cofilin Accelerates Actin Dynamics by Severing Filaments and Promoting Their Depolymerization at Both Ends. Curr. Biol. 2017, 27, 1956–1967.e7. [Google Scholar] [CrossRef] [Green Version]
  77. Bravo-Cordero, J.J.; Magalhaes, M.A.O.; Eddy, R.J.; Hodgson, L.; Condeelis, J. Functions of cofilin in cell locomotion and invasion. Nat. Rev. Mol. Cell Biol. 2013, 14, 405–417. [Google Scholar] [CrossRef] [Green Version]
  78. Walsh, K.P.; Kuhn, T.B.; Bamburg, J.R. Cellular prion protein: A co-receptor mediating neuronal cofilin-actin rod formation induced by b-amyloid and proinflammatory cytokines. Prion 2014, 8, 375–380. [Google Scholar] [CrossRef]
  79. Terra-Granado, E.; Berbert, L.R.; De Meis, J.; Nomizo, R.; Martins, V.R.; Savino, W.; Silva-Barbosa, S.D. Is there a role for cellular prion protein in intrathymic T cell differentiation and migration? Neuroimmunomodulation 2007, 14, 213–219. [Google Scholar] [CrossRef]
  80. Friedl, P.; Weigelin, B. Interstitial leukocyte migration and immune function. Nat. Immunol. 2008, 9, 960–969. [Google Scholar] [CrossRef]
  81. Schmitt-Ulms, G.; Legname, G.; Baldwin, M.A.; Ball, H.L.; Bradon, N.; Bosque, P.J.; Crossin, K.L.; Edelman, G.M.; DeArmond, S.J.; Cohen, F.E.; et al. Binding of neural cell adhesion molecules (N-CAMs) to the cellular prion protein. J. Mol. Biol. 2001, 314, 1209–1225. [Google Scholar] [CrossRef] [PubMed]
  82. Suter, D.M.; Forscher, P. Transmission of growth cone traction force through apCAM-cytoskeletal linkages is regulated by Src family tyrosine kinase activity. J. Cell Biol. 2001, 155, 427–438. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  83. Schmitt-Ulms, G.; Hansen, K.; Liu, J.; Cowdrey, C.; Yang, J.; DeArmond, S.J.; Cohen, F.E.; Prusiner, S.B.; Baldwin, M.A. Time-controlled transcardiac perfusion cross-linking for the study of protein interactions in complex tissues. Nat. Biotechnol. 2004, 22, 724–731. [Google Scholar] [CrossRef] [PubMed]
  84. Watts, J.C.; Huo, H.; Bai, Y.; Ehsani, S.; Won, A.H.; Shi, T.; Daude, N.; Lau, A.; Young, R.; Xu, L.; et al. Interactome analyses identify ties of prpc and its mammalian paralogs to oligomannosidic n-glycans and endoplasmic reticulum-derived chaperones. PLoS Pathog. 2009, 5. [Google Scholar] [CrossRef]
  85. Farina, F.; Botto, L.; Chinello, C.; Cunati, D.; Magni, F.; Masserini, M.; Palestini, P. Characterization of prion protein-enriched domains, isolated from rat cerebellar granule cells in culture. J. Neurochem. 2009, 110, 1038–1048. [Google Scholar] [CrossRef] [PubMed]
  86. Das, V.; Bhattacharya, S.; Chikkaputtaiah, C.; Hazra, S.; Pal, M. The basics of epithelial–mesenchymal transition (EMT): A study from a structure, dynamics, and functional perspective. J. Cell. Physiol. 2018, 234, 14535–14555. [Google Scholar] [CrossRef]
  87. Mehrabian, M.; Brethour, D.; Wang, H.; Xi, Z.; Rogaeva, E.; Schmitt-Ulms, G. The prion protein controls polysialylation of neural cell adhesion molecule 1 during cellular morphogenesis. PLoS One 2015, 10, 1–23. [Google Scholar] [CrossRef] [Green Version]
  88. Lehembre, F.; Yilmaz, M.; Wicki, A.; Schomber, T.; Strittmatter, K.; Ziegler, D.; Kren, A.; Went, P.; Derksen, P.W.B.; Berns, A.; et al. NCAM-induced focal adhesion assembly: A functional switch upon loss of E-cadherin. EMBO J. 2008, 27, 2603–2615. [Google Scholar] [CrossRef] [Green Version]
  89. Lambert, A.W.; Pattabiraman, D.R.; Weinberg, R.A. Emerging biological principles of metastasis. Cell 2017, 168, 670–691. [Google Scholar] [CrossRef] [Green Version]
  90. Lin, S.C.; Lin, C.H.; Shih, N.C.; Liu, H.L.; Wang, W.C.; Lin, K.Y.; Liu, Z.Y.; Tseng, Y.J.; Chang, H.K.; Lin, Y.C.; et al. Cellular prion protein transcriptionally regulated by NFIL3 enhances lung cancer cell lamellipodium formation and migration through JNK signaling. Oncogene 2020, 39, 385–398. [Google Scholar] [CrossRef]
  91. Simillis, C.; Kalakouti, E.; Afxentiou, T.; Kontovounisios, C.; Smith, J.J.; Cunningham, D.; Adamina, M.; Tekkis, P.P. Primary Tumor Resection in Patients with Incurable Localized or Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis. World J. Surg. 2019, 43, 1829–1840. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  92. Furnari, F.B.; Fenton, T.; Bachoo, R.M.; Mukasa, A.; Stommel, J.M.; Stegh, A.; Hahn, W.C.; Ligon, K.L.; Louis, D.N.; Brennan, C.; et al. Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes Dev. 2007, 21, 2683–2710. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  93. de Lacerda, T.C.S.; Costa-Silva, B.; Giudice, F.S.; Dias, M.V.S.; de Oliveira, G.P.; Teixeira, B.L.; dos Santos, T.G.; Martins, V.R. Prion protein binding to HOP modulates the migration and invasion of colorectal cancer cells. Clin. Exp. Metastasis 2016, 33, 441–451. [Google Scholar] [CrossRef] [PubMed]
  94. Hatoum, A.; Mohammed, R.; Zakieh, O. The unique invasiveness of glioblastoma and possible drug targets on extracellular matrix. Cancer Manag. Res. 2019, 11, 1843–1855. [Google Scholar] [CrossRef] [Green Version]
  95. Tan, H.L.; Chia, C.S.; Tan, G.H.C.; Choo, S.P.; Tai, D.W.M.; Chua, C.W.L.; Ng, M.C.H.; Soo, K.C.; Teo, M.C.C. Metastatic gastric cancer: Does the site of metastasis make a difference? Asia. Pac. J. Clin. Oncol. 2018, 15, 1–8. [Google Scholar] [CrossRef] [Green Version]
  96. Zbytek, B.; Carlson, J.A.; Granese, J.; Ross, J.; Mihm, M.; Slominski, A. Current concepts of metastasis in melanoma. Expert Rev. Dermatol. 2008, 3, 569–585. [Google Scholar] [CrossRef] [Green Version]
  97. Reni, M.; Mazza, E.; Zanon, S.; Gatta, G.; Vecht, C.J. Central nervous system gliomas. Crit. Rev. Oncol. Hematol. 2017, 113, 213–234. [Google Scholar] [CrossRef]
  98. Orditura, M.; Galizia, G.; Sforza, V.; Gambardella, V.; Fabozzi, A.; Laterza, M.M.; Andreozzi, F.; Ventriglia, J.; Savastano, B.; Mabilia, A.; et al. Treatment of gastric cancer. World J. Gastroenterol. 2014, 20, 1635–1649. [Google Scholar] [CrossRef]
  99. Lackey, A.; Donington, J. Surgical management of lung cancer. Semin. Intervent. Radiol. 2013, 30, 133–140. [Google Scholar] [CrossRef] [Green Version]
  100. Rentsch, M.; Schiergens, T.; Khandoga, A.; Werner, J. Surgery for colorectal cancer - Trends, developments, and future perspectives. Visc. Med. 2016, 32, 184–191. [Google Scholar] [CrossRef]
  101. Tohme, S.; Simmons, R.L.; Tsung, A. Surgery for Cancer: A Trigger for Metastases. Cancer Res. 2018, 77, 1548–1552. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  102. Alieva, M.; van Rheenen, J.; Broekman, M.L.D. Potential impact of invasive surgical procedures on primary tumor growth and metastasis. Clin. Exp. Metastasis 2018, 35, 319–331. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  103. Martin, T.; Ye, L.; Sanders, A.; Lane, J.; Jiang, W. Cancer Invasion and Metastasis: Molecular and Cellular Perspective. Metastatic Cancer Clin. Biol. Perspect. 2014, 9, 1–28. [Google Scholar]
  104. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  105. Wienberg, D.H.R.A. The Hallmarks of Cancer. Cell 2000, 100, 57–70. [Google Scholar]
  106. Peinado, H.; Lavotshkin, S.; Lyden, D. The secreted factors responsible for pre-metastatic niche formation: Old sayings and new thoughts. Semin. Cancer Biol. 2011, 21, 139–146. [Google Scholar] [CrossRef] [PubMed]
  107. Aplin, A.E.; Howe, A.; Alahari, S.K.; Juliano, R.L. Signal transduction and signal modulation by cell adhesion receptors: The role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol. Rev. 1998, 50, 197–263. [Google Scholar]
  108. Christofori, G.; Semb, H. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem. Sci. 1999, 24, 73–76. [Google Scholar] [CrossRef]
  109. Cavallaro, U.; Christofori, G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat. Rev. Cancer 2004, 4, 118–132. [Google Scholar] [CrossRef]
  110. Johnson, J.P. Cell adhesion molecules of the immunoglobulin supergene family and their role in malignant transformation and progression to metastatic disease. Cancer Metastasis Rev. 1991, 10, 11–22. [Google Scholar] [CrossRef]
  111. Varner, J.A.; Cheresh, D.A. Integrins and cancer. Curr. Opin. Cell Biol. 1996, 8, 724–730. [Google Scholar] [CrossRef]
  112. Werb, Z. ECM and cell surface proteolysis: Regulating cellular ecology. Cell 1997, 91, 439–442. [Google Scholar] [CrossRef] [Green Version]
  113. Karnoub, A.E.; Dash, A.B.; Vo, A.P.; Sullivan, A.; Brooks, M.W.; Bell, G.W.; Richardson, A.L.; Polyak, K.; Tubo, R.; Weinberg, R.A. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449, 557–563. [Google Scholar] [CrossRef] [PubMed]
  114. Kessenbrock, K.; Plaks, V.; Werb, Z. Matrix Metalloproteinases: Regulators of the tumor. Cell 2010, 141, 52–67. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  115. Qian, B.; Pollard, J.W. Macrophage Diversity Enhances Tumor Progression and Metastasis. Cell 2010, 141, 39–51. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  116. Wang, Q.; Qian, J.; Wang, F.; Ma, Z. Cellular prion protein accelerates colorectal cancer metastasis via the Fyn-SP1-SATB1 axis. Oncol. Rep. 2012, 28, 2029–2034. [Google Scholar] [CrossRef] [Green Version]
  117. Du, L.; Rao, G.; Wang, H.; Li, B.; Tian, W.; Cui, J.; He, L.; Laffin, B.; Tian, X.; Hao, C.; et al. CD44-positive cancer stem cells expressing cellular prion protein contribute to metastatic capacity in colorectal cancer. Cancer Res. 2013, 73, 2682–2694. [Google Scholar] [CrossRef] [Green Version]
  118. Chieng, C.K.L.; Say, Y.H. Cellular prion protein contributes to LS 174T colon cancer cell carcinogenesis by increasing invasiveness and resistance against doxorubicin-induced apoptosis. Tumor Biol. 2015, 36, 8107–8120. [Google Scholar] [CrossRef]
  119. Wang, Y.; Yu, S.; Huang, D.; Cui, M.; Hu, H.; Zhang, L.; Wang, W.; Parameswaran, N.; Jackson, M.; Osborne, B.; et al. Cellular Prion Protein Mediates Pancreatic Cancer Cell Survival and Invasion through Association with and Enhanced Signaling of Notch1. Am. J. Pathol. 2016, 186, 2945–2956. [Google Scholar] [CrossRef] [Green Version]
  120. Yang, L.; Gao, Z.; Hu, L.; Wu, G.; Yang, X.; Zhang, L.; Zhu, Y.; Wong, B.S.; Xin, W.; Sy, M.S.; et al. Glycosylphos-phatidylinositol anchor modification machinery deficiency is responsible for the formation of pro-prion protein (PrP) in BxPC-3 protein and increases cancer cell motility. J. Biol. Chem. 2016, 291, 3905–3917. [Google Scholar] [CrossRef] [Green Version]
  121. Li, C.; Yu, S.; Nakamura, F.; Yin, S.; Xu, J.; Petrolla, A.A.; Singh, N.; Tartakoff, A.; Abbott, D.W.; Xin, W.; et al. Binding of pro-prion to filamin A disrupts cytoskeleton and correlates with poor prognosis in pancreatic cancer. J. Clin. Invest. 2009, 119. [Google Scholar] [CrossRef] [PubMed]
  122. Ke, J.; Wu, G.; Zhang, J.; Li, H.; Gao, S.; Shao, M.; Gao, Z.; Sy, M.S.; Cao, Y.; Yang, X.; et al. Melanoma migration is promoted by prion protein via Akt-hsp27 signaling axis. Biochem. Biophys. Res. Commun. 2020, 523, 375–381. [Google Scholar] [CrossRef] [PubMed]
  123. Pan, Y.; Zhao, L.; Liang, J.; Liu, J.; Shi, Y.; Liu, N.; Zhang, G.; Jin, H.; Gao, J.; Xie, H.; et al. Cellular prion protein promotes invasion and metastasis of gastric cancer. FASEB J. 2006, 20, 1886–1888. [Google Scholar] [CrossRef] [PubMed]
  124. Gil, M.; Kim, Y.K.; Kim, K.E.; Kim, W.; Park, C.S.; Lee, K.J. Cellular prion protein regulates invasion and migration of breast cancer cells through MMP-9 activity. Biochem. Biophys. Res. Commun. 2016, 470, 213–219. [Google Scholar] [CrossRef] [PubMed]
  125. Cheng, Y.; Tao, L.; Xu, J.; Li, Q.; Yu, J.; Jin, Y.; Chen, Q.; Xu, Z.; Zou, Q.; Liu, X. CD44/Cellular prion protein interact in multidrug resistant breast cancer cells and correlate with responses to neoadjuvant chemotherapy in breast cancer patients. Mol. Carcinog. 2014, 53, 686–697. [Google Scholar] [CrossRef]
  126. Mangé, A.; Milhavet, O.; Umlauf, D.; Harris, D.; Lehmann, S. PrP-dependent cell adhesion in N2a neuroblastoma cells. FEBS Lett. 2002, 514, 159–162. [Google Scholar] [CrossRef]
  127. Dillekås, H.; Rogers, M.S.; Straume, O. Are 90% of deaths from cancer caused by metastases? Cancer Med. 2019, 8, 5574–5576. [Google Scholar] [CrossRef] [Green Version]
Ijms 21 06677 g001 550
Figure 1. Cellular prion protein (PrPC) participates in cell motility through interaction with several partners. PrPC can promote the activation of Fyn in a caveolin-1-dependent manner, although the exact mechanism is unknown. Additionally, PrPC can also modulate the activation of Scr. Since PrPC is a glycophosphatidylinositol (GPI)-anchored protein and all the aforementioned proteins are cytosolic, it is postulated the existence of a transmembrane adaptor that acts as an intermediator. Both Fyn and Src are essential for the regulation of Ras homolog family member A (RhoA) activity. In turn, RhoA has a role in the actin polymerization and assembly of F-actin, as well as the formation of cell protrusions such as focal adhesions (FA) with the presence of focal adhesion kinase (FAK), a central regulator of FA. At the tip of FAs is observed an agglomeration of PrPC, as well as integrins and, since PrPC is known to interact with molecules from the extracellular matrix (ECM), it is postulated that both proteins have an important role in adhesion to the extracellular matrix during cell movement. Additionally, PrPC is also known to modulate adhesiveness, being found at the tip of FA and co-localizing with key proteins in cell–cell adhesion domains such as occludin, claudin, PECAM and ZO-1. It is not yet clear if PrPC can interact homophilically with other PrPC molecules from the neighboring cells, although a co-localization is observed.
Figure 1. Cellular prion protein (PrPC) participates in cell motility through interaction with several partners. PrPC can promote the activation of Fyn in a caveolin-1-dependent manner, although the exact mechanism is unknown. Additionally, PrPC can also modulate the activation of Scr. Since PrPC is a glycophosphatidylinositol (GPI)-anchored protein and all the aforementioned proteins are cytosolic, it is postulated the existence of a transmembrane adaptor that acts as an intermediator. Both Fyn and Src are essential for the regulation of Ras homolog family member A (RhoA) activity. In turn, RhoA has a role in the actin polymerization and assembly of F-actin, as well as the formation of cell protrusions such as focal adhesions (FA) with the presence of focal adhesion kinase (FAK), a central regulator of FA. At the tip of FAs is observed an agglomeration of PrPC, as well as integrins and, since PrPC is known to interact with molecules from the extracellular matrix (ECM), it is postulated that both proteins have an important role in adhesion to the extracellular matrix during cell movement. Additionally, PrPC is also known to modulate adhesiveness, being found at the tip of FA and co-localizing with key proteins in cell–cell adhesion domains such as occludin, claudin, PECAM and ZO-1. It is not yet clear if PrPC can interact homophilically with other PrPC molecules from the neighboring cells, although a co-localization is observed.
Ijms 21 06677 g001
Ijms 21 06677 g002 550
Figure 2. Role of PrPC in neuronal plasticity. Upper panel: PrPC seems to interact with neural cell adhesion molecule (NCAM), promoting the recruitment of Fyn to lipid rafts and stimulating neurite outgrowth. Additionally, PrPC interaction with its well-known ligand, STI1, is able to modulate both Protein kinase A (PKA) and Mitogen-activated protein kinase (MAPK) pathways. The first one is shown to promote neuronal protection, while the second one promotes neuritogenesis. Lower panel: PrPC activated through a ligand or through antibody-mediated crosslinking is able to cluster in reggie microdomains, promoting the activation of Fyn and MAPK. Both of those proteins have an important role in the polarized transport of N-cadherin to regions of growth cone elongation, where it associates with reggie. Additionally, Ca2+ intake is also important to the modulation of this process.
Figure 2. Role of PrPC in neuronal plasticity. Upper panel: PrPC seems to interact with neural cell adhesion molecule (NCAM), promoting the recruitment of Fyn to lipid rafts and stimulating neurite outgrowth. Additionally, PrPC interaction with its well-known ligand, STI1, is able to modulate both Protein kinase A (PKA) and Mitogen-activated protein kinase (MAPK) pathways. The first one is shown to promote neuronal protection, while the second one promotes neuritogenesis. Lower panel: PrPC activated through a ligand or through antibody-mediated crosslinking is able to cluster in reggie microdomains, promoting the activation of Fyn and MAPK. Both of those proteins have an important role in the polarized transport of N-cadherin to regions of growth cone elongation, where it associates with reggie. Additionally, Ca2+ intake is also important to the modulation of this process.
Ijms 21 06677 g002
Table
Table 1. List of tumors along with respective PrPC functions associated with the modulation of invasion and metastasis process.
Table 1. List of tumors along with respective PrPC functions associated with the modulation of invasion and metastasis process.
Types of tumorPrPC function in tumor cell motility
ColorectalPrPC interacts with STI-1 to activate ERK1/2 and modulate migration and invasion [93]
PrPC interacts with laminin to activate MAPK pathway and induce EMT [117]
PrPC modulates E-cadherin and N-cadherin, as well as translocation of β-catenin to induce EMT [116]
PrPC has metastatic potential by triggering Fyn-SP1-SATB1 pathway [116]
ColonPrPC is involved in the cell adhesion to fibronectin and collagen to the ECM [118]
PrPC modulates E-cadherin and N-cadherin, as well as translocation of β-catenin to the nucleus, inducing EMT [116]
PrPC has metastatic potential by triggering Fyn-SP1-SATB1 pathway [116]
Pancreatic ductal adenocarcinomaPro-PrPC retains a GPI-anchor peptide signal sequence that crosses the plasma membrane [119,120,121]
Pro-PrPC interacts with Notch1 stimulating cell growth and invasion [119]
Pro-PrPC interacts with FLNa affecting cell motility [119,120,121]
MelanomaPro-PrPC retains a GPI-anchor peptide signal sequence that crosses the plasma membrane [122]
In FLNa deficient cells, PRNP expression affects cell migration [122]
PrPC modulates actin polymerization trough AKT and HSP27 [122]
GastricPrPC contributes to cell adhesion [123]
Through ERK1/2, PrPC modulates invasion and mRNA and protein levels of MMP11 [123]
Invasive lung adenocarcinomaPrPC is expressed in invasive tumors, but not in in situ tumors [90]
Enhanced PrPC expression in lamellipodia [90]
PrPC modulates Rac1 expression and cell migration [90]
PrPC modulates JNK pathways and induces cell motility [90]
Together with NFIL3, PrPC acts towards cancer cell migration [90]
BreastPrPC overexpression intensifies cell migration and invasiveness [124]
At higher expression PrPC upregulates MMP9 protein and mRNA levels through NF-kB and ERK pathways, contributing to cell motility [124]
Together with CD44, PrPC is involved in cell migration mechanisms through the proteins EGFR, CD147, MMP2 and MMP9 [125]
Glioblastoma multiformePrPC modulates recruitment of E-cadherin to the plasma membrane of GSCs [31]
PrPC modulates subcellular localization of β-catenin [31]
Changes in PrPC expression affects cell migration on laminin as well as integrin α6 expression [31]

Share and Cite

MDPI and ACS Style

Prado, M.B.; Melo Escobar, M.I.; Alves, R.N.; Coelho, B.P.; Fernandes, C.F.d.L.; Boccacino, J.M.; Iglesia, R.P.; Lopes, M.H. Prion Protein at the Leading Edge: Its Role in Cell Motility. Int. J. Mol. Sci. 2020, 21, 6677. https://doi.org/10.3390/ijms21186677

AMA Style

Prado MB, Melo Escobar MI, Alves RN, Coelho BP, Fernandes CFdL, Boccacino JM, Iglesia RP, Lopes MH. Prion Protein at the Leading Edge: Its Role in Cell Motility. International Journal of Molecular Sciences. 2020; 21(18):6677. https://doi.org/10.3390/ijms21186677

Chicago/Turabian Style

Prado, Mariana Brandão, Maria Isabel Melo Escobar, Rodrigo Nunes Alves, Bárbara Paranhos Coelho, Camila Felix de Lima Fernandes, Jacqueline Marcia Boccacino, Rebeca Piatniczka Iglesia, and Marilene Hohmuth Lopes. 2020. "Prion Protein at the Leading Edge: Its Role in Cell Motility" International Journal of Molecular Sciences 21, no. 18: 6677. https://doi.org/10.3390/ijms21186677

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop